1. Home
  2. KTTA vs MBRX Comparison

KTTA vs MBRX Comparison

Compare KTTA & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.46

Market Cap

18.1M

Sector

Health Care

ML Signal

HOLD

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

HOLD

Current Price

$2.21

Market Cap

16.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KTTA
MBRX
Founded
2020
2015
Country
United States
United States
Employees
5
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.1M
16.1M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
KTTA
MBRX
Price
$0.46
$2.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$3.00
$61.00
AVG Volume (30 Days)
570.7K
516.1K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.26
52 Week High
$2.06
$7.98

Technical Indicators

Market Signals
Indicator
KTTA
MBRX
Relative Strength Index (RSI) 29.39 39.55
Support Level $0.28 $1.99
Resistance Level $0.86 $2.64
Average True Range (ATR) 0.05 0.26
MACD -0.00 -0.07
Stochastic Oscillator 9.04 0.00

Price Performance

Historical Comparison
KTTA
MBRX

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: